Drugs

, Volume 36, Supplement 6, pp 148–154 | Cite as

Pharmacokinetics and Bioavailability of Carvedilol in Patients with Liver Cirrhosis

  • G. Neugebauer
  • M. Gabor
  • K. Reiff
Short Communication Poster Presentation

Keywords

Liver Cirrhosis Carvedilol Frusemide Systemic Clearance Liver Patient 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Franz J-W, Wiewel D, Kebelhut R. Antihypertensiver Effekt einer beta-blockierend und vasodilatorisch wirkenden Substanz auf Ruhe- und Belastungsblutdruck im Vergleich zur alleinigen Beta-Rezeptorenblockade. Verhandlungen der Deutschen Gesellschaft fur Innere Medizin 90(II): 750–752, 1984Google Scholar
  2. Neugebauer G, Akpan W, von Möllendorff E, Neubert P, Reiff K. Pharmacokinetics and disposition of carvedilol in humans. Journal of Cardiovascular Pharmacology 10 (Suppl. 11): S85–S88, 1987PubMedGoogle Scholar
  3. Reiff K. High-performance liquid chromatographic method for the determination of carvedilol and its desmethyl metabolite in body fluids. Journal of Chromatography 413: 355–362, 1987PubMedCrossRefGoogle Scholar
  4. von Möllendorff E, Sponer G, Strein K, Bartech W, Müller-Beckman B, et al. Carvedilol. In Scriabine A (Ed.) New cardiovascular drugs, pp. 135–153, Raven Press, New York, 1987Google Scholar

Copyright information

© ADIS Press Limited 1988

Authors and Affiliations

  • G. Neugebauer
    • 1
  • M. Gabor
    • 2
  • K. Reiff
    • 1
  1. 1.Department of Clinical PharmacologyBoehringer Mannheim GmbHMannheimGermany
  2. 2.Department of Internal MedicineMarienkrankenhausBergisch-GladbachGermany

Personalised recommendations